On Oct. 23, 2024, Pfizer announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee…
On Jun. 17, 2024, Merck announced that the U.S. Food and Drug Administration (FDA) had approved CAPVAXIVEâ„¢ (Pneumococcal…
On Apr. 3, 2024, the U.S. Food and Drug Administration approved Basilea Pharmaceutica’s Zevtera (ceftobiprole medocaril sodium for…
On Nov. 23, 2023, the World Health Organization (WHO) announced that it was monitoring data from Chinese surveillance…
On Sept. 14, 2023, the World Health Organization (WHO) reported that as of Sept. 11, 2023, a total…
On Sept. 6, 2023, the National Institutes of Health (NIH) announced it was investgating ‘hypervirulent’ strains of the…
On Apr. 14, 2023, the National Health Commission of the Peopleï¾’s Republic of China reported a confirmed case…
On Oct. 24, 2022, Merck announced that the European Commission had approved an expanded indication for VAXNEUVANCEï¾™ (Pneumococcal…
On Jul. 22, 2022, Gilead Sciences announced that the Committee for Medicinal Products for Human Use (CHMP) of…
On Jun. 22, 2022, Merck announced that that the U.S. Food and Drug Administration (FDA) had approved an…
On Apr. 14, 2022, Merck announced that V116, the companyï¾’s investigational 21-valent pneumococcal conjugate vaccine, had received Breakthrough…
On Mar. 31, 2022, Sorrento Therapeutics announced that the FDA had given clearance to commence the Phase 3…
On Feb. 15, 2022, Pfizer announced that the European Medicines Agency had approved the companyï¾’s 20-valent pneumococcal conjugate…
On Dec. 9, 2021, CytoDyn announced that it had submitted a Phase 3, randomized, double blind, placebo controlled…
On Oct. 18, 2021, a NIAID sponsored clinical trial found that treatment with the immunomodulator interferon beta-1a plus…
On Oct. 15, 2021, Merck announced that the European Medicines Agencyï¾’s Committee for Medicinal Products for Human Use…
On Aug. 3, 2021, Vanda Pharmaceuticals announced that enrollment had closed in the ODYSSEY study comparing tradipitant and…
On Jul. 16, 2021, Merck announced the U.S. Food and Drug Administration (FDA) had approved VAXNEUVANCE (Pneumococcal 15-valent…
On Jun. 21, 2021, Cumberland Pharma released a series of case reports describing the effectiveness of Vibativ (telavancin)…
On Jun. 16, 2021, Pfizer and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced…
On Jun. 8, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved PREVNAR 20ï¾™…
On Apr. 21, 2021,Trevena announced that TRV027, the Companyï¾’s novel AT1 receptor selective agonist, had been selected for…
On Feb. 26, 2021, Pfizer announced that the European Medicines Agency (EMA) accepted for review the Marketing Authorization…
On Feb. 23, 2021, Nabriva Therapeutics announced publication of a study documenting the high rates of macrolide-resistant Streptococcus…
On Jan. 29, 2021, Humanigen announced it had completed enrollment for its pivotal phase 3 study of lenzilumab…
On Jan. 15, 2021, scientists studying the bodyï¾’s natural defenses against bacterial infection announced they had identified a…
On Dec. 22, 2020, RedHill Biopharma announced that the global Phase 2/3 study with orally-administered opaganib (Yeliva, ABC294640)1…
On Dec. 8, 2020, Pfizer announced that the FDA accepted for priority review a Biologics License Application (BLA)…
On Nov. 25, 2020, RedHill Biopharma announced partnerships with two leading, U.S.-based manufacturers for large-scale manufacturing of opaganib….
On Nov. 16, 2020, RedHill Biopharma announced that the U.S. Phase 2 study with opaganib (Yeliva, ABC294640)1 in…